Carmell Corporation Completes Acquisition of Elevai Skincare
Carmell Corporation, renowned for its focus on skin and hair health, has successfully closed the acquisition of Elevai Skincare, expanding its presence in the bio-aesthetics market. Elevai is recognized for its innovation in physician-dispensed skin and hair care products, particularly those utilizing advanced exosome technology.
Details of the Acquisition
The acquisition involved a detailed purchase agreement with PMGC Holdings Inc., marking a significant step forward for Carmell. The purchase consideration was composed of a mix of stock and cash payments designed to reflect the value of Elevai's assets and expected future contributions to Carmell’s product lineup.
At the closing, Carmell issued approximately $1.1 million worth of its common stock, at a price of $0.8488 per share, alongside an agreement for an additional cash payment of around $57,000 tied to the sale of certain inventory. The structure of this acquisition not only strengthens Carmell's portfolio but also ensures that Elevai's existing contractual obligations are assumed as part of the transaction.
Post-Closing Considerations
The deal also lays out potential future earnout considerations. Carmell will receive 5% of net sales from Elevai’s product line for five years after the acquisition. Notably, there's a significant milestone payment of $500,000 if Elevai’s hair and scalp products succeed in generating $500,000 in net revenue within two years. This structure reflects a forward-looking strategy that aligns with Carmell's growth aspirations.
Strategic Benefits of the Acquisition
Rajiv Shukla, Carmell's Chairman, expressed optimism about the benefits from the acquisition. He emphasized that the transaction will enhance their product offerings, broaden their market reach, and positively impact their cash flow. These strategic advantages are expected to create synergies that unlock further growth and efficiency.
What Carmell Gained from Elevai
As part of this acquisition, Carmell has acquired valuable assets from Elevai, including a robust product portfolio that generated approximately $2.5 million in revenue in the last fiscal year, along with a dedicated commercial team and existing inventory. These resources will be pivotal as Carmell integrates Elevai's operations into its growth strategy.
Company Background and Future Prospects
Carmell Corporation is committed to advancing bio-aesthetic technology. The company utilizes its proprietary Carmell Secretome™, which consists of growth factors and proteins derived from allogeneic human platelets. This innovative approach places Carmell at the forefront of skin and hair health solutions. With future product lines in development, Carmell aims to cater to both professional care providers and discerning retail consumers, reinforcing its position in the competitive landscape.
Frequently Asked Questions
What does the acquisition of Elevai Skincare mean for Carmell?
The acquisition allows Carmell to diversify its product offerings and leverage Elevai's innovative technologies to enhance their market presence in skin and hair care.
How will the acquisition affect Carmell's financial situation?
The acquisition is expected to improve Carmell's cash flow and significantly impact their overall revenue, particularly through post-closing earnout agreements tied to Elevai’s product sales.
What products does Elevai offer that will benefit Carmell?
Elevai specializes in physician-dispensed skin and hair care products, notably those utilizing advanced exosome technology, which will complement Carmell’s existing portfolio.
Who is the Chairman of Carmell Corporation?
Rajiv Shukla serves as the Chairman of Carmell Corporation, overseeing the strategic direction of the company.
Where can I learn more about Carmell's products?
For more information about Carmell's innovative products and technologies, you can visit their official website at www.carmellcosmetics.com.
